Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

emfizatamab (GNC-038)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Biokin Pharma

Drug class:

PD-L1 inhibitor, CD3 agonist, CD19 inhibitor, CD137 agonist

Related drugs:

‹

atezolizumab (236)

durvalumab (198)

sugemalimab (7)

envafolimab (6)

IO102-IO103 (4)

atezolizumab/hyaluronidase (1)

CF33-hNIS-antiPDL1 (0)

PD-L1.t-haNK (0)

PF-07257876 (0)

blinatumomab (52)

epcoritamab-bysp (11)

elranatamab-bcmm (8)

mosunetuzumab-axgb (2)

talquetamab-tgvs (2)

teclistamab-cqyv (2)

glofitamab-gxbm (1)

JNJ-63898081 (1)

ABBV-383 IV (0)

CD30 biAb-AATC (0)

JNJ-63709178 (0)

JNJ-67571244 (0)

PF-06671008 (0)

PF-07062119 (0)

PF-07260437 (0)

catumaxomab (0)

UMG2-CD3 BTCE (0)

Undisclosed HER2Bi-armed ATC (0)

activated CIK and bispecific antibody (0)

activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody (0)

huCD33-BsAb (0)

tafasitamab-cxix (3)

BTN2A1/3A1-Fc-CD19scFv (0)

CAR-NK-CD19 cells (0)

CB CAR-NK019 (0)

CD19.t-haNK (0)

Imtox19/Imtox22 (0)

inebilizumab-cdon (0)

anti CD19/CD22 CAR NK cells (0)

autologous TRAC locus-inserted CD19-STAR-T (0)

dualCAR-NK19/70 (0)

universal chimeric antigen receptor-modified AT19 cells (0)

ALG.APV-527 (1)

PF-08046049 (1)

PF-05082566 (1)

›